How do you market a drug for a disease that will make most people squirm? Well, Tarsus isn’t shying away from the topic and is going all out on its new campaign aimed at a condition caused by a skin ...
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize ...
Tarsus runs new 'Don’t Freak Out. Get Checked Out' eyelid disease campaign as FDA approval beckons
Tarsus is gearing up for a potential FDA green light of its experimental drug to treat a common but little-known eyelid inflammation disease and is wasting no time to boost awareness around the ...
An executive at Tarsus Pharmaceuticals sold 12,274 shares for a transaction value of approximately $839,000, based on a weighted average price of $68.36 per share across three days ending March 19, ...
As part of its latest eye care campaign, Tarsus Pharmaceuticals has a simple message for patients with demodex blepharitis: Don’t Freak Out, Get Checked Out. Since May is Health Vision Month, the ...
22d
Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Moves And Ongoing Losses
Recent performance and business snapshot Tarsus Pharmaceuticals (TARS) has attracted fresh attention after recent trading, with the stock closing at US$70.12 and showing mixed share price moves over ...
A common eyelid disease caused by infestation with tiny parasitic mites that live in hair follicles now has its first approved treatment in the US. Tarsus Pharmaceuticals' Xdemvy (lotilaner) has ...
Tarsus CEO Bobby Azamian, along his executive team and his wife, Blair, and their 6-week-old newborn, Auggie, ring the closing bell at Nasdaq What better way for a drugmaker to tell Wall Street about ...
Tarsus Pharmaceuticals is tackling a common eyelid condition that affects millions of Americans as part of its recently launched Look at the Lids campaign. The educational effort targets demodex ...
Tarsus Pharmaceuticals Inc. delivered higher-than-expected fourth quarter revenue driven by surging demand for its eyedrop Xdemvy. More than two years into commercial launch, sales of Xdemvy, the ...
Tarsus Pharmaceuticals has performed an aggressive marketing push for Xdemvy in Demodex blepharitis. Read why TARS stock is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results